Wuhan Renfu Likang Pharmaceutical Co., Ltd.

Wuhan Renfu Likang Pharmaceutical Co., Ltd. was established in January 2016 with a registered capital of 150 million yuan. It is a formulation manufacturing enterprise certified to both NMPA and U.S. FDA standards, as well as an open pharmaceutical formulation CDMO/CMO and MAH incubation service platform. It focuses on contract development and manufacturing services for innovative drug formulations, small-batch formulations, clinical samples, and drug MAH, and is a high-quality asset of the Humanwell Healthcare Group. The company currently has a two-story comprehensive formulation building with a total construction area of approximately 5,736 ㎡; a first-floor aseptic injection workshop of approximately 1,300 ㎡; a second-floor solid formulation workshop of approximately 1,140 ㎡; a laboratory area of approximately 790 ㎡; and a total warehouse area of approximately 330 ㎡. The company currently has four production lines, and the dosage forms produced include tablets, hard capsules, lyophilized powder injections, and small-volume injections. The tablet production line has a capacity of 150 million tablets per year, the hard capsule production line has a capacity of 150 million capsules per year, the lyophilized powder injection production line has a capacity of 1.5 million vials per year, and the small-volume injection production line has a capacity of 6 million vials per year.